Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 12 March 2009, Vol. 113, No. 11, pp. 2372-2373.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roth, J. J.
Right arrow Articles by Buchberg, A. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Roth, J. J.
Right arrow Articles by Buchberg, A. M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

MYELOID NEOPLASIA

Comment on Faber et al, page 2375

Might as well face it: MLL's addicted to HOX

Jacquelyn J. Roth, Richard C. Crist, and Arthur M. Buchberg

THOMAS JEFFERSON UNIVERSITY

Overexpression of HOXA9 is a hallmark of MLL-rearranged leukemias. In this issue of Blood, Faber and colleagues show that HOXA9 is critical for proliferation and survival of leukemic cells.

Chromosomal rearrangements involving the MLL gene are a characteristic feature of a variety of human leukemias, including acute lymphoid (ALL) and acute myeloid leukemias (AML) as well as secondary leukemias resulting from treatment with topoisomerase inhibitors.1 The MEIS1 and HOXA9 genes have been shown to be major downstream targets of MLL fusion proteins.2 The mammalian HOX genes encode DNA-binding homeobox proteins that have a role in developmental patterns and tissue fate during embryogenesis. MEIS1 is a homeodomain protein that acts as a DNA-binding cofactor of HOX proteins from paralog groups 9 through 13.3 MEIS1 and HOXA genes are normally expressed in hematopoietic progenitor cells and their expression is down-regulated on differentiation.4 Overexpression of MEIS1 and HOXA9 is seen in a variety of leukemic cell lines and primary AML samples, suggesting roles for these genes in leukemia initiation and maintenance.5 In addition, fusion of HOXA9 to NUP98 in some AMLs further supports an important role for HOXA9 in leukemia.6

In this issue of Blood, Faber et al ask if HOXA9 expression is required to maintain the leukemic state.7 The authors investigated the effects of knocking down HOXA9 expression in MLL-rearranged and nonrearranged human leukemia cells. After shRNA-mediated HOXA9 suppression, induction of apoptosis and decreased colony formation were observed in leukemia cell lines. An increase of cells in the G1 phase of the cell cycle and some cellular differentiation was also observed prior to the cells undergoing apoptosis. The apoptotic phenotype was rescued by expression of nontargetable HOXA9. The authors demonstrated that a greater induction of cell death was observed in MLL-rearranged cell lines and primary AML samples compared with MLL germ line cells after shRNA knockdown of HOXA9. In addition, the level of apoptosis positively correlated with levels of HOXA9 expression prior to shRNA knockdown. Gene expression profiling on MLL-rearranged cells after knockdown of HOXA9 expression showed decreased expression of genes, such as MEIS1 and PBX3, previously shown to play a role in leukemogenesis, suggesting these genes are downstream of HOXA9. Finally, MLL-rearranged cells were subjected to knockdown of HOXA9 and transplanted into mice. These mice showed a significant decrease in leukemia burden, demonstrating that continued HOXA9 expression is required for survival and proliferation of human MLL-rearranged cells in vivo.

The results provided by Faber et al demonstrate that MLL-rearranged cells are addicted to HOXA9 expression to maintain their leukemic state, as shown in the figure. Another major downstream target of MLL fusion proteins is MEIS1.2 Previous work done by Wong et al and work by Kumar et al used similar strategies to demonstrate that maintenance of the leukemic state in MLL-rearranged cells is also dependent on expression of MEIS1.8,9 Knockdown of MEIS1 expression results in decreased proliferation and survival of these cells. Although MEIS1 is important in maintenance of the leukemic state, elevated levels of MEIS1 are not sufficient to induce leukemia.10 In contrast, elevated levels of HOXA9 are sufficient to induce leukemia with a long latency.10 Coexpression of MEIS1 along with HOXA9, however, reduces the latency of HOX-induced leukemia.4 Taken together, these data suggest a role for both MEIS1 and HOXA9 in leukemia initiation and maintenance.


Figure 1
View larger version (22K):
[in this window]
[in a new window]

 
Leukemias arising from MLL translocations have a characteristic signature of increased HOXA9 and MEIS1 expression. Maintenance of the leukemic state requires continued expression of both genes. Knockdown of either HOXA9 or MEIS1 expression results in a loss of leukemogenic potential.

 
The data from the gene expression profiling experiment in Faber et al suggest that MEIS1 is downstream of HOXA9. Is continued HOXA9 expression required to maintain high levels of MEIS1 expression in leukemic cells? Knockdown of HOXA9 expression in MLL-rearranged cells and simultaneous ectopic expression of MEIS1 will further elucidate the complex interactions of these transcription factors in leukemia maintenance. Clarification of this gene partnership will lead to an understanding of gene regulation in MLL-rearranged leukemias. MEIS1 and HOXA9 have been shown to function as a heterodimer and in higher order complexes. Small molecule inhibitors could provide alternate therapeutic strategies by disrupting MEIS1/HOXA9 dimer formation, leading to loss of proliferation and survival in MLL-rearranged leukemic cells.

Footnotes

Conflict-of-interest disclosure: The authors declare no competing financial interests. {blacksquare}

REFERENCES

  1. Super HJ, McCabe NR, Thirman ML, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 1993;82:3705–3711.[Abstract/Free Full Text]

  2. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nature Genetics. 2002;30:41–47.[CrossRef][Medline] [Order article via Infotrieve]

  3. Shen WF, Montgomery JC, Rozenfeld S, et al. AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins. Mol Cell Biol. 1997;17:6448–6458.[Abstract]

  4. Thorsteinsdottir U, Kroon E, Jerome L, et al. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21:224–234.[Abstract/Free Full Text]

  5. Lawrence HJ, Rozenfeld S, Cruz C, et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia. 1999;13:1993–1999.[CrossRef][Medline] [Order article via Infotrieve]

  6. Nakamura T, Largaespada DA, Lee MP, et al. Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia. Nature Genetics. 1996;12:154–158.[CrossRef][Medline] [Order article via Infotrieve]

  7. Faber J, Krivtsov AV, Stubbs MC, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood. 2009;113:2375–2385.[Abstract/Free Full Text]

  8. Kumar AR, Li Q, Hudson WA, et al. A role for MEIS1 in MLL-fusion gene leukemia. Blood. 2009;113:1756–1758.[Abstract/Free Full Text]

  9. Wong P, Iwasaki M, Somervaille TCP, et al. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21:2762–2774.[Abstract/Free Full Text]

  10. Kroon E, Krosl J, Thorsteinsdottir U, et al. HoxA9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17:3714–3725.[CrossRef][Medline] [Order article via Infotrieve]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

HOXA9 is required for survival in human MLL-rearranged acute leukemias
Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis, Marry van den Heuvel-Eibrink, Christian M. Zwaan, Andrew L. Kung, and Scott A. Armstrong
Blood 2009 113: 2375-2385. [Abstract] [Full Text] [PDF]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roth, J. J.
Right arrow Articles by Buchberg, A. M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Roth, J. J.
Right arrow Articles by Buchberg, A. M.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020